Back to Type 2 Diabetes
NCT01043029
NCT01043029
Who may be able to join
Who might be able to join this trial:
- You must be 18 years of age or older
- You must have been diagnosed with Type 2 diabetes
- You must have moderately reduced kidney function
- You must either be taking no diabetes medications, or be on up to 2 diabetes medications at a steady dose for more than 1 month before the screening visit
- Your Body Mass Index (BMI, a measure of body weight relative to height) must be between 25 and 35
Who may not be able to join:
- You have ever taken a type of diabetes medication called a thiazolidinedione (such as pioglitazone or rosiglitazone)
- You currently use or have previously used insulin to manage your blood sugar
- You have taken medications called fibrates (a type of cholesterol-lowering drug) within the 3 months before the screening visit
- You have a history of kidney disease that was caused by something other than your diabetes
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 2
Sponsor
Hoffmann-La Roche
Registry
clinicaltrials_gov
Start date
1 May 2010
Est. completion
1 July 2012
Where this trial is recruiting
🇦🇺 Australia
🇧🇷 Brazil
🇨🇴 Colombia
El Salvador
🇩🇪 Germany
Hong Kong
🇭🇺 Hungary
🇮🇹 Italy
🇲🇽 Mexico
🇵🇪 Peru
🇷🇴 Romania
🇷🇺 Russia
🇸🇰 Slovakia
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Renal function: estimated glomerular filtration rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.